N-Acyl Glucosamine Derivatives for Oral Bone and Joint Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis and arthritis, such as glucosamine-based compounds, face limitations in improving bone mineral density (BMD) and bone microarchitecture, and glucosamine derivatives suffer from poor pharmacokinetic properties like low oral bioavailability and rapid clearance, necessitating high doses and limited therapeutic efficacy.
Innovation Solution
Development of glucosamine butyryl (GlcNBu) derivatives and prodrugs, represented by compounds of Formulae (A), (I), (II), (III), and (IV), which enhance bioavailability, stability, and reduce metabolism, thereby increasing therapeutic efficacy for bone and joint disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucosamine-based compounds are used to treat osteoporosis and arthritis, then therapeutic effects are achieved, but pharmacokinetic properties deteriorate with low oral bioavailability and rapid clearance
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of glucosamine derivatives through N-acylation with specific fatty acids (C2-C18 chains). This structural modification changes the pharmacokinetic parameters of the compound, improving oral bioavailability and reducing metabolic clearance while maintaining therapeutic efficacy for osteoporosis and arthritis treatment
Solution Approach 2:
The patent creates composite chemical structures by combining glucosamine with various acyl groups (fatty acid chains of different lengths and saturations). These composite glucosamine derivatives exhibit improved pharmacokinetic properties compared to plain glucosamine, achieving better absorption and stability profiles
2Quantity of substance
If glucosamine derivatives are administered at high doses to overcome poor pharmacokinetics, then bioavailability increases, but therapeutic effectiveness remains limited
Solution Approach 1:
The patent modifies molecular parameters of glucosamine by introducing N-acyl groups with specific chain lengths (C2-C18). This parameter change optimizes the balance between bioavailability and therapeutic effectiveness, allowing lower doses to achieve better clinical outcomes compared to high-dose plain glucosamine administration
3Quantity of substance
If current osteoporosis treatments such as bi-phosphonates are used, then bone mineral density increases, but bone microarchitecture and connectivity remain unchanged
Solution Approach 1:
The patent employs parameter changes in the chemical structure of glucosamine derivatives to achieve a dual effect: increasing bone mineral density while simultaneously improving bone microarchitecture and connectivity. The N-acyl glucosamine structures modify cellular processes involved in both bone formation and structural organization
Solution Approach 2:
The patent creates multi-functional glucosamine derivatives that simultaneously address multiple aspects of bone health: increasing mineral density, improving microarchitecture, and enhancing connectivity. This universal agent replaces the need for separate treatments targeting different bone parameters
Data Source
AI summary
There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis.